International Journal of Scientific Research Updates

Journal homepage: https://orionjournals.com/ijsru/

ISSN: 2783-0160 (Online)

ORION SCHOLAR JOURNALS

(REVIEW ARTICLE)

Check for updates

Convergence of AI, blockchain and pharmacoeconomics in building adaptive pharmaceutical supply chains: A novel paradigm shift for equitable global drug access

Adeleke Damilola Adekola [1, *], Rinji Goshit Kassem [2] and Akachukwu Obianuju Mbata [3]

[1] *Boehringer Ingelheim, Nigeria.*
[2] *Vanderbilt University, USA.*
[3] *Kaybat Pharmacy and Stores, Benin, Nigeria.*

International Journal of Scientific Research Updates, 2022, 04(01), 356-374

Publication history: Received on 16 August 2022; revised on 22 September 2022; accepted on 25 September 2022

Article DOI: https://doi.org/10.53430/ijsru.2022.4.1.0142

Abstract

The convergence of Artificial Intelligence (AI), blockchain technology, and pharmacoeconomics presents a transformative opportunity to revolutionize pharmaceutical supply chains, fostering equitable global drug access. Traditional supply chains are often plagued by inefficiencies, including limited transparency, suboptimal resource allocation, and susceptibility to counterfeit drugs, which exacerbate disparities in drug availability. This paper explores a novel paradigm where AI-driven analytics, blockchain's immutable ledgers, and pharmacoeconomic principles synergize to create adaptive pharmaceutical supply chains tailored to global needs. AI facilitates predictive analytics for demand forecasting, inventory optimization, and real-time decision-making, reducing wastage and ensuring timely drug delivery. Blockchain enhances transparency and traceability across the supply chain, ensuring the authenticity of pharmaceutical products and fostering stakeholder trust. Concurrently, pharmacoeconomics evaluates the cost-effectiveness of supply chain strategies, balancing affordability with accessibility. This interdisciplinary framework enables equitable distribution of essential medications, particularly in underserved regions, by addressing systemic challenges such as logistical inefficiencies, pricing disparities, and regulatory compliance. The proposed approach leverages AI to identify demand patterns and optimize supply routes, while blockchain ensures secure, verifiable records of drug production, distribution, and delivery. Integrating pharmacoeconomic assessments informs pricing models and reimbursement strategies that align with socio-economic realities, thus promoting affordability without compromising sustainability. Case studies from pilot implementations highlight the potential for reduced operational costs, enhanced drug traceability, and improved access to life-saving medications. By combining the strengths of AI, blockchain, and pharmacoeconomics, this framework offers a scalable, resilient, and adaptive model for pharmaceutical supply chains, addressing global health inequities. It underscores the importance of collaboration among stakeholders, including governments, healthcare providers, and technology innovators, in advancing healthcare outcomes. Future research should explore the ethical implications, technological scalability, and policy frameworks necessary to ensure the widespread adoption of this integrated paradigm.

Keywords: Pharmaceutical supply chains; Artificial Intelligence (AI); Blockchain; Pharmacoeconomics; Equitable drug access; Global health; Adaptive logistics; Predictive analytics; Drug traceability; Healthcare innovation

1. Introduction

The global pharmaceutical supply chain faces numerous challenges that hinder the equitable distribution of essential medicines, particularly in underserved regions. Issues such as inefficiencies in logistics, lack of transparency, susceptibility to counterfeit drugs, and resource allocation imbalances contribute to disparities in drug availability and affordability (Alemede, Usuemerai & Ibikunle, 2022, Ighodaro & Scott, 2013, Onochie, 2020). These challenges

* Corresponding author: Adeleke Damilola Adekola.

underscore the urgent need for innovative solutions to ensure that lifesaving medications are accessible to all, regardless of geographical or socio-economic barriers. Equitable access to medicines is a cornerstone of global health, and addressing these systemic obstacles is critical for achieving universal healthcare goals.

Emerging technologies such as Artificial Intelligence (AI), blockchain, and pharmacoeconomics offer transformative potential to reimagine pharmaceutical supply chains. AI can leverage predictive analytics and machine learning to optimize inventory management, demand forecasting, and logistical operations, enabling supply chains to adapt dynamically to changing needs (Agrawal, et al., 2016). Blockchain technology, with its decentralized and immutable nature, enhances transparency, traceability, and security across supply chains, reducing the risk of counterfeit drugs and fostering trust among stakeholders (Ighodaro & Agbro, 2010, Ighodaro, Ochornma & Egware, 2020). Pharmacoeconomics, which focuses on evaluating the cost-effectiveness of healthcare interventions, plays a vital role in developing sustainable pricing models and ensuring that medications remain affordable while maintaining supply chain efficiency. Together, these domains create an opportunity for unprecedented innovation in pharmaceutical supply chain management.

This paper introduces a novel framework that integrates AI, blockchain, and pharmacoeconomics to build adaptive pharmaceutical supply chains aimed at achieving equitable global drug access. By leveraging the synergies between these technologies, the proposed paradigm addresses key inefficiencies and inequities in current systems while fostering sustainability and resilience (Amimo, et al., 2021). The focus is on advancing global health equity by ensuring that essential medicines are distributed effectively and affordably to all regions. This integrated approach underscores the need for collaboration among technology developers, healthcare providers, policymakers, and other stakeholders to realize a shared vision of equitable healthcare delivery.

2. Challenges in Traditional Pharmaceutical Supply Chains

The traditional pharmaceutical supply chain, which serves as the backbone of global healthcare delivery, is rife with challenges that compromise its efficiency, transparency, and equity. These systemic issues not only hinder the timely distribution of essential medicines but also exacerbate existing disparities in healthcare access. As the world becomes increasingly interconnected, addressing these challenges is crucial for creating a sustainable and adaptive pharmaceutical supply chain capable of meeting global health demands.

One of the most pressing challenges in traditional pharmaceutical supply chains is inefficiency, stemming from outdated logistical processes and fragmented systems. These inefficiencies manifest in several ways, including delays in drug delivery, excessive inventory holding costs, and wastage of perishable medicines. Many pharmaceutical supply chains operate with limited visibility across their various nodes, from manufacturers and distributors to healthcare providers and patients (Alemede, Usuemerai & Ibikunle, 2022, Elujide, et al., 2021, Ighodaro, 2010). This lack of transparency inhibits real-time decision-making, leading to bottlenecks, stockouts, and overstocking, all of which compromise the timely availability of medicines. Without comprehensive data integration and communication, stakeholders are unable to respond effectively to changing demands or disruptions, further amplifying inefficiencies.

Another critical issue is the prevalence of counterfeit drugs and quality assurance failures within traditional supply chains. Counterfeit medicines not only pose significant health risks but also undermine trust in healthcare systems. The World Health Organization (WHO) estimates that one in ten medical products in low- and middle-income countries is substandard or falsified, a statistic that underscores the pervasive nature of this issue (Anyika, 2014). Traditional supply chains often lack robust mechanisms for verifying the authenticity of drugs at every stage, from manufacturing to end-user delivery. This gap in quality control is compounded by the absence of secure traceability systems, making it difficult to identify and remove counterfeit products from circulation (Ighodaro & Egware, 2014, Onochie, 2019). The infiltration of substandard drugs into the supply chain not only jeopardizes patient safety but also imposes economic burdens on healthcare systems, as resources are diverted to address the consequences of such failures. Iyamu, et al., 2022, presented a mutually reinforcing pillars of digital public health as shown in figure 1.



Figure 1 Mutually reinforcing pillars of digital public health (Iyamu, et al., 2022).

Resource allocation and demand-supply mismatches further exacerbate the inefficiencies in pharmaceutical supply chains. In many regions, particularly in low-income countries, supply chains struggle to align production and distribution with actual healthcare needs. These mismatches arise from a combination of poor demand forecasting, inadequate infrastructure, and logistical constraints (Ighodaro, 2016, Ighodaro, Scott & Xing, 2017). For instance, rural areas often face significant delays in receiving essential medicines due to transportation challenges and limited storage facilities. Conversely, urban centers may experience overstocking of certain drugs, leading to wastage and increased costs. The inability to accurately predict demand and allocate resources efficiently not only results in financial losses but also limits access to critical medications for vulnerable populations.

Affordability and pricing inequities are additional challenges that plague traditional pharmaceutical supply chains. The cost of medicines remains a significant barrier to access for millions of people worldwide, particularly in low- and middle-income countries. Pricing disparities often stem from complex supply chain structures, high production costs, and the monopolistic practices of pharmaceutical companies (Arden, et al., 2021). These factors contribute to wide variations in drug prices across different regions, with low-income countries frequently paying more for the same medications compared to wealthier nations (Ighodaro & Osikhuemhe, 2019, Onochie, et al., 2017). Moreover, the lack of standardized pricing mechanisms and limited regulatory oversight allows for significant markups at various points in the supply chain, further inflating costs for end users. The financial burden of high drug prices disproportionately affects marginalized communities, limiting their ability to access life-saving treatments and perpetuating health inequities.

The cumulative impact of these challenges highlights the urgent need for innovation in pharmaceutical supply chain management. The inefficiencies and lack of transparency that characterize traditional systems not only hinder operational effectiveness but also compromise the ability of healthcare providers to respond to emergencies and evolving public health needs. The pervasive issue of counterfeit drugs underscores the critical importance of enhancing traceability and quality assurance mechanisms to protect patient safety and build trust in healthcare systems (Kwasi-Effah, et al., 2022, Onochie, et al., 2022). Addressing resource allocation and demand-supply mismatches requires the adoption of advanced forecasting and logistical solutions to ensure that medicines are distributed equitably and efficiently. Finally, tackling affordability and pricing inequities necessitates the development of sustainable pricing models and regulatory frameworks that prioritize access and affordability without compromising the financial viability of pharmaceutical companies.

In summary, the traditional pharmaceutical supply chain is beset by a myriad of challenges that impede its ability to deliver equitable and efficient healthcare outcomes. Inefficiencies, lack of transparency, counterfeit drugs, resource allocation mismatches, and pricing inequities collectively undermine the system's capacity to meet global health demands. Addressing these challenges requires a concerted effort to integrate innovative technologies and strategies that can transform the supply chain into a more adaptive, transparent, and equitable system (Ardill, et al., 2022). By leveraging advancements in AI, blockchain, and pharmacoeconomics, it is possible to overcome these obstacles and build a supply chain framework that ensures the timely and affordable delivery of essential medicines to all, thereby advancing global health equity.

3. Theoretical Framework

The convergence of Artificial Intelligence (AI), blockchain technology, and pharmacoeconomics provides a robust theoretical framework for addressing the inefficiencies and inequities of traditional pharmaceutical supply chains. By leveraging the unique capabilities of these three domains, it is possible to build adaptive, resilient, and equitable supply chain systems capable of ensuring global access to essential medicines. Each of these technologies contributes distinct strengths that, when integrated, can fundamentally transform pharmaceutical supply chains.

AI plays a critical role in optimizing pharmaceutical supply chains through advanced analytics, predictive modeling, and automation. Demand forecasting, for instance, is an area where AI demonstrates exceptional value by analyzing vast datasets to predict medication needs accurately. Factors such as population health trends, seasonal variations in illnesses, and emergency scenarios can be assessed in real time to ensure that drug production and distribution align with actual demand (Ighodaro & Essien, 2020, Onochie & Ighodaro, 2017). This capability reduces the risk of stockouts, overproduction, and wastage, thereby enhancing the efficiency and responsiveness of supply chains. Similarly, AI-driven inventory management systems can monitor stock levels, identify discrepancies, and recommend optimal reorder points, ensuring continuous availability of medicines. Furthermore, AI can optimize logistical operations by determining the most efficient routes for transportation, accounting for variables such as traffic, weather conditions, and storage requirements for temperature-sensitive drugs. These capabilities not only improve supply chain efficiency but also reduce operational costs, enabling broader access to affordable medicines.

Blockchain technology complements AI by providing the transparency and security necessary for building trust and integrity within pharmaceutical supply chains. One of its most significant contributions is the traceability of drug provenance and distribution. By recording every transaction on an immutable ledger, blockchain ensures that all stakeholders, from manufacturers to end-users, can verify the authenticity and journey of a drug (Aruru, Truong & Clark, 2021). This traceability is particularly crucial in combating the proliferation of counterfeit medicines, which pose significant risks to public health and undermine trust in healthcare systems. Blockchain's decentralized nature ensures that no single entity can manipulate data, enhancing data integrity and reliability (Agupugo & Tochukwu, 2021, Ighodaro & Akhihiero, 2021). Furthermore, the technology fosters stakeholder trust by enabling secure data sharing across the supply chain. Manufacturers, regulators, distributors, and healthcare providers can access critical information in real time, facilitating collaboration and ensuring compliance with regulatory standards. By enhancing transparency and security, blockchain not only strengthens the resilience of pharmaceutical supply chains but also empowers patients and healthcare providers with the confidence that the medicines they use are safe and effective. A chart on new Paradigm Shift in Treatment as presented by Roxon, 2018, is shown in figure 2.



Figure 2 New Paradigm Shift in Treatment (Roxon, 2018)

Pharmacoeconomics adds another dimension to this framework by focusing on cost-effectiveness analysis and resource utilization within pharmaceutical supply chains. This discipline evaluates the economic value of healthcare interventions, helping stakeholders determine the most efficient allocation of resources to maximize health outcomes. One of the primary applications of pharmacoeconomics is the development of affordable pricing models that balance cost recovery for pharmaceutical companies with accessibility for patients (Egware, Ighodaro & Unuareokpa, 2016, Ighodaro, Okogie & Ozakpolor, 2010). By analyzing production costs, market dynamics, and the socio-economic profiles of target populations, pharmacoeconomics can inform pricing strategies that ensure equitable access to medicines. Additionally, it provides insights into resource utilization, identifying areas where efficiency can be improved to reduce costs without compromising quality or availability. For example, pharmacoeconomic analyses can help prioritize the distribution of high-impact drugs during public health emergencies, ensuring that limited resources are deployed effectively to save lives (Barbosa, Woetzel & Mischke, 2017).

Beyond pricing and resource allocation, pharmacoeconomics also plays a crucial role in assessing the socio-economic impacts of pharmaceutical supply chains. By quantifying the broader economic benefits of improved drug access, such as increased productivity and reduced healthcare costs, it provides a compelling case for investments in adaptive supply chain systems. These assessments help policymakers and stakeholders understand the long-term value of equitable drug access, encouraging the adoption of strategies and technologies that promote health equity (Barcevičius, et al., 2019). Moreover, pharmacoeconomics can guide the integration of AI and blockchain technologies by evaluating their cost-effectiveness and potential impact on supply chain performance. This ensures that technological innovations are not only feasible but also sustainable in the context of global healthcare needs.

The integration of AI, blockchain, and pharmacoeconomics creates a synergistic framework that addresses the multifaceted challenges of pharmaceutical supply chains. AI's predictive and optimization capabilities ensure that supply chains are responsive and efficient, while blockchain's transparency and security features build trust and safeguard against counterfeit drugs. Pharmacoeconomics provides the economic insights necessary to ensure that these innovations translate into affordable and equitable access to medicines. Together, these technologies form a holistic approach that enhances every aspect of the pharmaceutical supply chain, from production and distribution to pricing and access.

This convergence also highlights the importance of collaboration among diverse stakeholders, including pharmaceutical companies, technology providers, regulators, and healthcare organizations. For the theoretical framework to succeed in practice, these stakeholders must work together to implement integrated solutions that leverage the strengths of AI, blockchain, and pharmacoeconomics (Agupugo, et al., 2022, Ighodaro & Orumwense, 2022). This requires not only technological investments but also policy and regulatory support to create an enabling environment for innovation. For example, governments and international organizations can play a pivotal role by establishing standards for blockchain implementation, incentivizing the adoption of AI-driven supply chain solutions, and supporting pharmacoeconomic research to inform policy decisions.

The theoretical framework also emphasizes the need for scalability and adaptability. While the integration of AI, blockchain, and pharmacoeconomics can address current challenges, it must also be flexible enough to respond to future demands and disruptions. This includes the ability to scale solutions to meet the needs of diverse populations and healthcare systems, from high-income countries with advanced infrastructure to low-income regions with limited resources. It also involves anticipating and mitigating emerging risks, such as cybersecurity threats to blockchain systems or ethical concerns related to AI-driven decision-making. By prioritizing scalability and adaptability, the framework ensures that pharmaceutical supply chains remain resilient and responsive in an ever-changing global landscape.

In conclusion, the convergence of AI, blockchain, and pharmacoeconomics represents a transformative approach to building adaptive pharmaceutical supply chains that advance equitable global drug access. AI optimizes supply chain operations through predictive analytics and automation, while blockchain ensures transparency, security, and trust. Pharmacoeconomics provides the economic insights necessary to develop sustainable pricing models and assess the broader impact of supply chain innovations (Bates, et al., 2014). Together, these technologies address the inefficiencies, inequities, and vulnerabilities of traditional systems, creating a robust framework for ensuring that essential medicines are accessible to all. By fostering collaboration, scalability, and adaptability, this theoretical framework lays the foundation for a new era of pharmaceutical supply chains that prioritize health equity and resilience.

4. Methodology

The methodology for exploring the convergence of AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains involves a multi-disciplinary approach to ensure a comprehensive framework that addresses efficiency, security, and equitable access. The process integrates qualitative and quantitative research techniques, data analysis, model development, and validation to provide a structured pathway for implementation.

The research design combines both qualitative and quantitative methods to capture the complexity of pharmaceutical supply chains and the potential of integrating advanced technologies. Qualitative approaches include stakeholder interviews, focus group discussions, and thematic analysis to understand the challenges and opportunities within existing supply chains. These insights inform the contextual relevance of AI, blockchain, and pharmacoeconomics applications. Quantitative methods, on the other hand, involve statistical analyses and computational modeling to test hypotheses and validate proposed solutions. This dual approach ensures a robust framework that is grounded in real-world challenges while leveraging the precision of data-driven methodologies (Alemede, Usuemerai & Ibikunle, 2022, Osarobo & Chika, 2016).

Data collection plays a pivotal role in the methodology, with a focus on existing pharmaceutical supply chain datasets, case studies, and pilot projects. Data from supply chain operations, such as production volumes, distribution patterns, and demand fluctuations, are analyzed to identify inefficiencies and vulnerabilities. In addition, data on counterfeit drugs, pricing disparities, and resource allocation inform targeted interventions. Case studies in underserved regions provide critical insights into the unique challenges faced by low-resource settings, such as logistical barriers and limited infrastructure (Berman, et al., 2021). Pilot projects in these areas enable the testing of technological innovations and their impact on supply chain performance. By incorporating diverse data sources, the methodology ensures that the proposed framework is applicable across various contexts and scales.

Model development is a central component of the methodology, encompassing the design of AI algorithms, blockchain protocols, and pharmacoeconomic models. AI-driven algorithms are developed for predictive analytics and decision-making, with applications in demand forecasting, inventory optimization, and route planning. Machine learning techniques are employed to analyze historical and real-time data, enabling dynamic adjustments to supply chain operations (Chanchaichujit, et al., 2019). Blockchain protocols are designed to ensure secure data handling, traceability, and transparency. Smart contracts and decentralized ledgers facilitate efficient collaboration among stakeholders while mitigating risks associated with counterfeit drugs and data tampering (Onyiriuka, et al., 2019, Orumwense, Ighodaro & Abo-Al-Ez, 2021). Pharmacoeconomic models are developed to evaluate cost-effectiveness, assess pricing strategies, and analyze the socio-economic impact of supply chain interventions. These models incorporate factors such as production costs, market dynamics, and health outcomes to guide resource allocation and policy decisions. The integration of these models creates a cohesive framework that addresses multiple dimensions of pharmaceutical supply chain management.

Validation and testing are essential to assess the effectiveness of the proposed framework. Simulations of supply chain scenarios are conducted to evaluate the performance of AI algorithms, blockchain protocols, and pharmacoeconomic models under varying conditions. These scenarios include emergency responses, routine operations, and resource-constrained environments to ensure the framework's adaptability and resilience. Metrics such as efficiency, scalability, and equity outcomes are used to measure the impact of the interventions. For instance, efficiency is assessed by analyzing reductions in lead times, inventory wastage, and logistical costs (Ighodaro & Scott, 2017, Onochie, et al., 2017). Scalability is evaluated by testing the framework's performance across different population sizes, geographic regions, and healthcare systems. Equity outcomes are measured by examining improvements in access to essential medicines for underserved populations. Feedback from simulations informs iterative refinements to the framework, ensuring its alignment with real-world needs and constraints.

The methodology also emphasizes collaboration with stakeholders, including pharmaceutical companies, healthcare providers, regulators, and technology developers. Workshops and collaborative platforms are organized to align the interests and expertise of these stakeholders, fostering a shared vision for equitable drug access. Stakeholder input is incorporated into the design and validation processes to ensure that the framework is practical, feasible, and aligned with regulatory and ethical standards.

A critical aspect of the methodology is addressing potential challenges and limitations. For instance, the integration of AI, blockchain, and pharmacoeconomics requires substantial investments in infrastructure, technical expertise, and regulatory compliance. The methodology incorporates a phased implementation approach, starting with pilot projects and gradually scaling up to broader applications. Additionally, ethical considerations related to data privacy, algorithmic bias, and accessibility are prioritized in the framework's development and validation (Dash, et al., 2019). Policies and guidelines are established to ensure that the framework adheres to ethical principles and regulatory standards while addressing the diverse needs of stakeholders.

In conclusion, the methodology for integrating AI, blockchain, and pharmacoeconomics in pharmaceutical supply chains is a comprehensive and iterative process that combines qualitative and quantitative research, data analysis, model development, and validation. By leveraging advanced technologies and interdisciplinary insights, the methodology aims to create a scalable and adaptive framework that enhances efficiency, security, and equity in global drug access. Through collaboration, stakeholder engagement, and continuous refinement, the proposed framework addresses the complexities of pharmaceutical supply chains while prioritizing the goal of equitable healthcare for all.

5. Case Studies and Implementation

Case studies and implementation of the convergence of AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains provide crucial insights into the practical application of this innovative framework. Through pilot projects and real-world applications, the potential for enhancing global drug access and addressing the inequities in pharmaceutical supply chains becomes evident. These initiatives also shed light on the challenges encountered during implementation and the critical success factors that contribute to achieving meaningful outcomes (Elujide, et al., 2021, Ighodaro & Aburime, 2011).

Pilot projects serve as the foundation for demonstrating the efficacy of AI-driven forecasting and inventory optimization in pharmaceutical supply chains. For instance, a project conducted in Sub-Saharan Africa utilized machine learning algorithms to predict demand for antiretroviral medications. Historical data, including disease prevalence rates and treatment adherence trends, were analyzed to generate precise demand forecasts. These forecasts enabled better allocation of resources, reduced stockouts, and minimized wastage of perishable drugs (Asibor & Ighodaro, 2019, Ighodaro, Olaosebikan & Egware, 2020). AI algorithms further optimized inventory levels by dynamically adjusting to variations in supply chain conditions, such as transportation delays or sudden spikes in demand due to disease outbreaks. The success of this pilot project highlighted the transformative potential of AI in enhancing supply chain responsiveness and efficiency.

Blockchain-based traceability systems have also been implemented in various contexts to improve transparency and security in pharmaceutical supply chains. A notable pilot project in Southeast Asia focused on combating counterfeit drugs by integrating blockchain technology into the supply chain for vaccines. A decentralized ledger was established to record every transaction along the supply chain, from manufacturing to distribution. Each vaccine batch was assigned a unique digital identifier, allowing stakeholders to verify its provenance and authenticity at every stage (Kwasi-Effah, et al., 2022, Onyeke, et al., 2022). Smart contracts ensured compliance with quality standards and regulatory requirements, while immutable records provided an auditable trail of the entire supply chain. This project demonstrated how blockchain could significantly reduce the risks associated with counterfeit drugs and foster trust among stakeholders.

The lessons learned from these pilot projects underscore the critical success factors and challenges associated with implementing AI, blockchain, and pharmacoeconomics in pharmaceutical supply chains. One of the most significant success factors is stakeholder collaboration. The involvement of pharmaceutical companies, healthcare providers, regulators, and technology developers was instrumental in ensuring the successful deployment of these technologies. Collaborative workshops and training sessions facilitated knowledge sharing and capacity building among stakeholders, addressing the technical and operational challenges encountered during implementation (De Boeck, et al., 2022). Stakeholders' commitment to a shared vision of equitable drug access also played a pivotal role in overcoming resistance to change and securing buy-in for the initiatives.

Another success factor is the adaptability of the technologies to diverse contexts. The AI algorithms used in demand forecasting, for example, were customized to account for regional variations in disease burden and healthcare infrastructure. Similarly, the blockchain systems were designed to operate efficiently in low-resource settings, with minimal reliance on high-speed internet or advanced computational hardware. This adaptability ensured the scalability and sustainability of the projects, enabling their replication in other regions and healthcare systems.

Despite these successes, several challenges emerged during the implementation of these pilot projects. One of the primary challenges was the lack of standardized data and interoperability among different systems. Many pharmaceutical supply chains operate with fragmented and siloed data, making it difficult to integrate AI and blockchain technologies seamlessly. Addressing this challenge required significant investments in data harmonization and the development of interoperable platforms (De Castro, et al., 2021). Another challenge was the resistance to adopting new technologies, particularly in low-resource settings where stakeholders were unfamiliar with AI and blockchain. Overcoming this resistance involved extensive capacity-building efforts, including training programs and awareness campaigns to demonstrate the benefits of these technologies.

Financial constraints also posed a significant barrier to implementation, especially in resource-limited contexts. The upfront costs of deploying AI and blockchain systems, such as infrastructure investments and software development, were often prohibitive for many stakeholders. To address this challenge, innovative financing models were explored, including public-private partnerships and donor funding. These models helped distribute the financial burden and ensure the long-term viability of the projects.

Pharmacoeconomics played a critical role in these pilot projects by providing a framework for evaluating cost-effectiveness and guiding resource allocation. For example, in the Sub-Saharan Africa project, pharmacoeconomic models were used to assess the impact of AI-driven demand forecasting on healthcare outcomes and cost savings. These models demonstrated that the initial investments in AI technologies were offset by reductions in drug wastage and improvements in treatment coverage (Elbadawi, et al., 2021). Similarly, the blockchain project in Southeast Asia utilized pharmacoeconomic analyses to quantify the benefits of traceability systems in preventing counterfeit drugs and enhancing patient safety. These analyses provided compelling evidence to justify the adoption of these technologies and informed policy decisions regarding their scale-up.

In conclusion, the case studies and pilot projects illustrate the transformative potential of converging AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains. The successes achieved in demand forecasting, inventory optimization, and traceability demonstrate how these technologies can address critical challenges in pharmaceutical supply chains and enhance global drug access. However, the implementation of these technologies also highlights significant challenges, including data interoperability, resistance to change, and financial constraints. By addressing these challenges and leveraging the lessons learned, stakeholders can create scalable and sustainable solutions that contribute to equitable healthcare access worldwide. The insights gained from these initiatives serve as a valuable blueprint for future efforts to integrate advanced technologies into pharmaceutical supply chains, ensuring that the goal of global health equity remains within reach.

6. Discussion

The convergence of AI, blockchain, and pharmacoeconomics represents a novel paradigm for addressing the persistent challenges in pharmaceutical supply chains, with significant implications for equitable global drug access. This discussion synthesizes key findings, identifies the transformative potential of these technologies, and examines the challenges and limitations that must be navigated for successful implementation.

One of the most compelling insights emerging from this convergence is its ability to improve access to essential medicines. AI-powered demand forecasting and inventory management have demonstrated their capacity to address critical inefficiencies in supply chains. By leveraging machine learning algorithms, pharmaceutical companies can accurately predict demand patterns, ensuring timely distribution of drugs to regions with the greatest need. This not only reduces the occurrence of stockouts but also minimizes wastage caused by overproduction or expiration (Ighodaro & Osikhuemhe, 2019, Onochie, et al., 2017). Enhanced inventory optimization enabled by AI facilitates equitable resource allocation, particularly in underserved areas, thereby bridging the gap in global healthcare access.

Blockchain technology further contributes to improved access through its emphasis on transparency and security. In regions plagued by counterfeit drugs, blockchain-based systems establish traceability across the supply chain, ensuring that only authentic products reach patients. By providing an immutable ledger of transactions, blockchain fosters trust among stakeholders, from manufacturers to end-users (Euchi, 2021). The integration of smart contracts further enhances operational efficiency, automating compliance checks and reducing the likelihood of errors. These attributes collectively strengthen supply chain integrity, contributing to greater availability and accessibility of high-quality medicines.

Pharmacoeconomics plays a crucial role in evaluating the cost-effectiveness of these interventions. By applying economic principles to healthcare, pharmacoeconomic models assess the impact of AI and blockchain technologies on healthcare outcomes and costs. For example, cost-utility analyses can demonstrate how investments in predictive analytics reduce the economic burden of supply chain inefficiencies, while cost-benefit analyses highlight the long-term financial advantages of adopting blockchain for drug traceability (Van Rensburg, 2014). These findings provide evidence-based guidance for stakeholders, ensuring that technological innovations are aligned with broader goals of affordability and equity.

Despite these promising developments, the convergence of AI, blockchain, and pharmacoeconomics is not without challenges and limitations. One significant barrier is the technological complexity associated with implementing these advanced systems. AI and blockchain require robust digital infrastructure, which is often lacking in low-resource settings. For example, AI algorithms rely on high-quality data, yet many pharmaceutical supply chains suffer from fragmented and incomplete datasets (Whitney, 2022). Addressing these challenges demands substantial investments in data harmonization and capacity building, which may not always be feasible for stakeholders operating in constrained environments.

Ethical considerations also present significant hurdles. The deployment of AI and blockchain technologies raises concerns about data privacy and security. Blockchain's transparency, while advantageous for traceability, can inadvertently expose sensitive information if not properly managed. Ensuring compliance with data protection regulations, such as GDPR, requires careful design and implementation of these systems. Additionally, the use of AI in decision-making processes, such as prioritizing drug distribution, must be guided by ethical frameworks to prevent biases and ensure equitable outcomes.

Regulatory barriers further complicate the adoption of these technologies. The pharmaceutical industry is heavily regulated, with stringent requirements for quality assurance, safety, and efficacy. While blockchain and AI offer mechanisms to streamline compliance processes, their adoption often requires regulatory bodies to adapt and update existing frameworks (Tzenios, 2019). This can be a slow and resource-intensive process, especially in regions with limited regulatory capacity. Harmonizing global standards for these technologies is critical to facilitate cross-border collaborations and ensure their widespread adoption.

Another limitation is the financial cost associated with implementing AI, blockchain, and pharmacoeconomic models. The initial investments in infrastructure, software development, and personnel training can be prohibitive for many organizations, particularly in low- and middle-income countries. Innovative financing mechanisms, such as public-private partnerships and donor funding, are essential to overcome these barriers. However, the sustainability of these funding models remains a concern, as long-term success depends on the ability to generate ongoing value from these technologies.

Furthermore, the human factor plays a pivotal role in the success of these initiatives. Resistance to change among stakeholders, particularly in traditional supply chain environments, can hinder the adoption of new technologies. Addressing this resistance requires comprehensive stakeholder engagement and capacity-building efforts, including training programs and awareness campaigns (Sun & Zhang, 2022). Creating a shared understanding of the benefits and potential of these technologies is essential to fostering buy-in and collaboration.

Despite these challenges, the convergence of AI, blockchain, and pharmacoeconomics offers a unique opportunity to reimagine pharmaceutical supply chains. By addressing inefficiencies, enhancing transparency, and promoting cost-effectiveness, this approach has the potential to transform global healthcare delivery. The key to realizing this vision lies in adopting a holistic and collaborative approach that leverages the strengths of each technology while mitigating their limitations.

Looking ahead, several strategies can help maximize the impact of this convergence. First, investing in digital infrastructure and data standardization is essential to enable the effective deployment of AI and blockchain technologies. Collaborative efforts among governments, industry players, and non-governmental organizations can accelerate these investments, ensuring that they reach the regions that need them most (Shafique, et al., 2018). Second, integrating ethical considerations into the design and implementation of these systems can build trust and safeguard against potential misuse. For example, adopting privacy-preserving technologies, such as zero-knowledge proofs, can enhance blockchain's transparency while protecting sensitive data.

Third, fostering regulatory innovation is critical to creating an enabling environment for these technologies. Regulatory sandboxes, which allow for controlled testing of new technologies, can facilitate their integration into existing frameworks without compromising safety or efficacy standards. Engaging with regulatory bodies early in the development process can also ensure that their concerns are addressed and that the technologies align with policy objectives.

Finally, leveraging the power of partnerships can amplify the impact of these initiatives. Collaborative platforms that bring together diverse stakeholders, including pharmaceutical companies, healthcare providers, and technology developers, can facilitate knowledge sharing and co-creation of solutions. Public-private partnerships can also help mobilize resources and distribute risks, enabling the successful implementation and scale-up of these technologies (Seshaiyer & McNeely, 2020).

In conclusion, the convergence of AI, blockchain, and pharmacoeconomics represents a transformative paradigm for building adaptive pharmaceutical supply chains. The key findings from this convergence highlight its potential to improve access, transparency, and cost-effectiveness, addressing critical gaps in global healthcare delivery. However, significant challenges and limitations, including technological, ethical, and regulatory barriers, must be addressed to realize its full potential. By adopting a strategic and collaborative approach, stakeholders can overcome these obstacles and harness the power of these technologies to advance equitable global drug access, ultimately contributing to better health outcomes for all.

6.1. Policy and Governance Implications

The convergence of AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains offers transformative potential to improve access, transparency, and cost-effectiveness in global drug distribution. However, to fully realize this potential, it is essential to address the policy and governance implications that arise from these advancements. The integration of these technologies into the pharmaceutical supply chain requires a coordinated approach involving governments, the private sector, international organizations, and other key stakeholders (Egware, et al., 2021, Ighodaro & Egbon, 2021). Alongside this, regulatory and ethical considerations must be carefully navigated to ensure that these systems are implemented equitably, securely, and in compliance with established standards.

A crucial component of the successful implementation of AI, blockchain, and pharmacoeconomics is the need for collaborative stakeholder engagement. Governments play an essential role in creating the policy framework that governs the use of these technologies. They are responsible for establishing regulations that facilitate innovation while safeguarding public health (Ighodaro, et al., 2022, Okagbare, Omotehinse & Ighodaro, 2022). Governments can foster collaboration by creating policy incentives for private sector involvement, including financial support for research and development, as well as funding for the infrastructure necessary to implement AI and blockchain-based solutions in supply chains. Through public-private partnerships, governments can support pilot projects, facilitate data-sharing agreements, and align their healthcare goals with technological advancements.

The private sector, particularly pharmaceutical companies and technology developers, also has a key role to play. Pharmaceutical companies must ensure that their supply chains are optimized for efficiency and that the implementation of AI and blockchain is in line with best practices for security, traceability, and patient safety. Technology developers bring expertise in building and deploying AI and blockchain solutions, creating the necessary infrastructure and software for these systems to function effectively. Collaboration between these two sectors can foster innovation while ensuring that AI and blockchain technologies are adopted in a manner that respects regulatory frameworks and promotes efficiency. Moreover, private-sector investment in new technologies can help overcome the resource constraints often faced by governments in low-income settings, where healthcare access remains a significant challenge.

International organizations such as the World Health Organization (WHO) and the Global Fund play a pivotal role in promoting the global adoption of AI, blockchain, and pharmacoeconomics in pharmaceutical supply chains. These organizations are instrumental in driving consensus around the adoption of international standards and best practices (WHO, 2016). By facilitating the exchange of knowledge and data across borders, they can support low- and middle-income countries in building the infrastructure needed for these technologies (Bello, et al., 2022, Ighodaro, Aburime & Erameh, 2022). Additionally, international organizations can work to bridge the gaps between different regulatory environments, ensuring that pharmaceutical products are treated equally across jurisdictions. They can also advocate for the equitable distribution of these technologies, ensuring that access is not restricted to high-income countries but is extended to underserved regions that would benefit most from improvements in supply chain efficiency and drug access. Horgan, et al., 2020, presented a Personalised health care (HC) mosaic. SME, small and medium enterprises; PM, personalised medicine as shown in figure 3.



Figure 3 Personalised health care (HC) mosaic. SME, small and medium enterprises; PM, personalised medicine (Horgan, et al., 2020)

Regulatory and ethical considerations are integral to the success of AI, blockchain, and pharmacoeconomics in adaptive pharmaceutical supply chains. One of the key concerns that arise with the use of these technologies is data privacy. Pharmaceutical supply chains generate massive amounts of data, ranging from patient information to inventory records. Ensuring the privacy of this data is paramount, particularly when dealing with sensitive health information. AI and blockchain technologies must be designed to comply with data protection laws, such as the General Data Protection Regulation (GDPR) in Europe and similar legislation in other regions (Ighodaro & Egwaoje, 2020, Onochie, Obanor & Ighodaro, 2017). Blockchain's transparency, which is one of its key advantages, must be balanced against the need to protect personally identifiable information (PII). Developing privacy-preserving blockchain solutions, such as zero-knowledge proofs or confidential transactions, can help to mitigate these concerns while still enabling the traceability and accountability that blockchain offers.

Compliance with regulatory standards is another critical concern. The pharmaceutical industry is one of the most heavily regulated sectors, with stringent requirements for safety, quality, and efficacy. The integration of AI and blockchain into supply chains must align with existing regulations governing drug distribution and manufacturing. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), must adapt their frameworks to accommodate the use of new technologies (Kaul & Khurana, 2022, Roxon, 2018). This may include developing new guidelines for the use of AI in decision-making processes, particularly regarding inventory management, demand forecasting, and drug distribution. Similarly, blockchain-based traceability systems must meet the regulatory requirements for drug safety, ensuring that all participants in the supply chain are compliant with national and international standards (Sarker, et al., 2021). Close collaboration between technology developers, pharmaceutical companies, and regulatory agencies will be necessary to ensure that these new technologies are integrated into the pharmaceutical supply chain in a way that adheres to all safety and quality regulations.

Ethical considerations also need to be addressed to ensure that AI and blockchain solutions do not inadvertently exacerbate existing inequities in healthcare access. One of the most significant risks is that these technologies could widen the gap between high-income and low-income countries if they are not implemented with an equity-driven focus. For instance, AI algorithms may be trained on data that is not representative of populations in low-resource settings, leading to biased predictions that do not meet the needs of these populations (Iyamu, et al., 2022, Riahi, et al., 2021). Similarly, blockchain systems could be inaccessible to regions without sufficient technological infrastructure, leaving underserved areas further marginalized. To mitigate these risks, policymakers must ensure that AI and blockchain systems are developed and deployed in ways that prioritize global equity. This could involve creating inclusive frameworks for data collection, ensuring that AI systems are trained on diverse datasets, and providing financial and technical support to low-income countries to help them build the infrastructure required to access these technologies.

Affordability is another ethical concern in the implementation of these technologies. While AI and blockchain have the potential to reduce costs and improve the efficiency of pharmaceutical supply chains, the upfront investment required to develop and deploy these technologies could be a barrier for countries with limited resources. Policymakers must explore mechanisms for financing the adoption of AI, blockchain, and pharmacoeconomics in low- and middle-income countries. Public-private partnerships, donor funding, and international cooperation can play a critical role in overcoming financial barriers (Horgan, et al., 2020, Parouty, 2018). Furthermore, equitable pricing models for these technologies must be established to ensure that they are accessible to all countries, regardless of income level. Ensuring that the benefits of these technologies are widely distributed will be key to achieving global health equity.

The role of governance in the successful implementation of AI, blockchain, and pharmacoeconomics is to provide a framework for ethical decision-making and equitable access. Governments must balance the need for innovation with the necessity of protecting public health, ensuring that these technologies are implemented in a way that prioritizes safety, security, and fairness. Engaging a broad range of stakeholders in the policy-making process, including public health experts, technology developers, pharmaceutical companies, and civil society organizations, will help to ensure that these technologies are deployed in a manner that benefits all populations.

In conclusion, the policy and governance implications of the convergence of AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains are complex but critical to ensuring their successful implementation. Collaborative stakeholder engagement is essential for fostering the necessary partnerships and aligning efforts across sectors. Regulatory and ethical considerations, particularly with respect to data privacy, compliance, and equity, must be carefully addressed to ensure that these technologies are deployed responsibly (Hope, 2017, Nursimulu, 2019). With appropriate policies and governance structures in place, AI, blockchain, and pharmacoeconomics have the potential to transform pharmaceutical supply chains, making essential medicines more accessible and affordable to populations worldwide. By addressing these policy challenges, global drug access can be improved, contributing to better health outcomes for all.

6.2. Future Directions

The convergence of AI, blockchain, and pharmacoeconomics in pharmaceutical supply chains presents a promising avenue for addressing some of the most pressing challenges in global health. As the world continues to grapple with issues of access, affordability, and equity in healthcare, the integration of these technologies offers transformative potential to optimize supply chains, reduce inefficiencies, and enhance the accessibility of essential medicines (Helo & Hao, 2022, Modgil, Singh & Hannibal, 2022). However, to realize this potential on a global scale, several critical factors must be addressed, including the scaling of the model across diverse regions, the ongoing technological innovations and integration necessary for improving these systems, and the long-term impact on global health equity.

Scaling the convergence of AI, blockchain, and pharmacoeconomics globally remains one of the most significant challenges. While there is substantial interest in these technologies in high-income countries, many low- and middle-income regions still face substantial barriers to access and infrastructure (Greenwood, 2014, Micalo, 2022). The challenge lies not only in the technical aspects of scaling but also in the socio-economic and regulatory landscapes that vary from one country to another. To ensure that these technologies are beneficial on a global scale, it is essential to create scalable frameworks that can be adapted to different regional contexts (Egware, Onochie & Ighodaro, 2016, Ighodaro & Aregbe, 2017). This involves building flexible, modular solutions that can be tailored to the specific needs of individual countries or regions, accounting for their unique healthcare infrastructures, economic conditions, and regulatory environments. Governments and international organizations will need to collaborate to facilitate the widespread adoption of these technologies, especially in underserved areas where access to healthcare remains a significant challenge. One potential avenue for scaling these solutions globally is through public-private partnerships that can leverage the expertise and resources of both the public and private sectors to overcome barriers to adoption. Additionally, donor organizations, international health bodies, and philanthropic organizations can play an important role in supporting these efforts by funding initiatives, providing technical expertise, and creating incentives for the adoption of AI, blockchain, and pharmacoeconomics solutions in low-income countries.

Technological innovations and integration will be key to improving the efficiency and effectiveness of pharmaceutical supply chains in the future. AI, blockchain, and pharmacoeconomics are already showing promise in improving aspects such as inventory management, drug traceability, cost-effectiveness, and demand forecasting, but much more can be achieved through continuous innovation. For instance, AI is increasingly being used to analyze vast amounts of data from the supply chain and predict demand, identify potential shortages, and optimize inventory (Ginsburg & Phillips, 2018, Mettler & Naous, 2022). This can reduce waste, improve availability, and ensure that drugs reach the right place at the right time. However, as healthcare data becomes more complex and diverse, AI algorithms must be continually refined and enhanced to account for changing patterns in healthcare delivery, population health needs, and the dynamics of global pharmaceutical markets. Additionally, as AI models become more advanced, issues such as algorithmic bias and fairness will need to be carefully considered to ensure that the technologies benefit all populations, not just those represented in the data.

Blockchain technology, with its ability to provide transparency, security, and immutability, will continue to play a central role in improving pharmaceutical supply chains. As the pharmaceutical industry faces increasing challenges related to counterfeiting and fraud, blockchain can offer an effective solution by enabling the secure tracking of drugs from manufacturing to distribution and ultimately to patients (Gichuki, 2021, Maureen, 2017). However, the future of blockchain in pharmaceutical supply chains lies not only in improving traceability but also in integrating blockchain with other emerging technologies, such as IoT (Internet of Things) and smart contracts. IoT-enabled devices, for example, can be used to track the temperature and storage conditions of drugs, ensuring their quality throughout the supply chain. Smart contracts, powered by blockchain, can automate transactions, reducing the need for intermediaries and speeding up processes while ensuring compliance with regulations. The integration of blockchain with AI will also enhance predictive capabilities, enabling more proactive management of supply chain risks and inefficiencies.

Pharmacoeconomics, which focuses on evaluating the cost-effectiveness of healthcare interventions, will also continue to evolve in tandem with AI and blockchain technologies. In the future, pharmacoeconomic models will need to incorporate more granular data, considering not only the direct costs of medicines but also the broader socio-economic impacts of drug access and distribution (Garbuio & Lin, 2018, Kulkov, 2021). This will include factors such as healthcare access, infrastructure, social determinants of health, and the long-term impact of pharmaceutical interventions on population health. Integrating AI into pharmacoeconomics will allow for more sophisticated analyses of these factors, enabling policymakers to make more informed decisions about drug pricing, resource allocation, and the design of equitable healthcare policies (Alemede, Usuemerai & Ibikunle, 2022, Ighodaro & Saale, 2017, Onochie, et al., 2018). As pharmacoeconomics becomes more integrated with AI and blockchain, it will provide more real-time insights into the performance of pharmaceutical supply chains and the effectiveness of drug distribution systems, supporting more adaptive and responsive healthcare systems globally.

The long-term impact of the convergence of AI, blockchain, and pharmacoeconomics on global health equity is profound. These technologies hold the potential to significantly reduce disparities in healthcare access and outcomes, particularly in low-income countries. By improving supply chain efficiency, reducing costs, and enhancing transparency, these technologies can help ensure that essential medicines reach the populations that need them most (Ganesh & Kalpana, 2022, Krumholz, 2014). One of the most significant ways in which AI, blockchain, and pharmacoeconomics can improve health equity is by enabling more personalized and data-driven healthcare delivery. AI can help predict the health needs of different populations, allowing for more targeted and equitable distribution of healthcare resources. Pharmacoeconomics, by evaluating the cost-effectiveness of drugs, can ensure that medicines are priced in a way that is affordable to both governments and patients, while blockchain can ensure that these drugs are not diverted, counterfeit, or wasted.

Furthermore, the integration of these technologies could also promote greater stakeholder collaboration, with governments, private sector players, international organizations, and non-governmental organizations working together to optimize the supply chain and promote equitable access. In the future, AI and blockchain could create a more decentralized pharmaceutical ecosystem, empowering local communities, regional players, and national health systems to have greater control over drug access, pricing, and distribution. This could lead to more resilient healthcare systems, particularly in regions that are currently underserved by traditional pharmaceutical supply chains.

Despite the immense potential of AI, blockchain, and pharmacoeconomics in building adaptive pharmaceutical supply chains, there remain challenges that must be addressed to achieve long-term sustainability and equity. The implementation of these technologies requires significant investment, not only in infrastructure and technology but also in education and capacity building for local stakeholders. Additionally, there must be careful consideration of the ethical, regulatory, and social implications of deploying these technologies, ensuring that they are used to promote fairness, equity, and transparency (Feitshans, 2022, Kolluri, et al., 2022). These technologies should not exacerbate existing inequalities but rather work to reduce them, ensuring that every person, regardless of where they live or their socio-economic status, has access to the medicines they need for good health.

In conclusion, the convergence of AI, blockchain, and pharmacoeconomics in pharmaceutical supply chains represents a novel paradigm that holds great promise for advancing global health equity. As these technologies continue to evolve and integrate, they will offer powerful tools for addressing the challenges of drug access, affordability, and transparency. Scaling these solutions globally, driving technological innovation, and ensuring long-term positive impacts on health equity will require ongoing collaboration, investment, and thoughtful policy development. If successfully implemented, these technologies could usher in a new era of equitable, efficient, and transparent pharmaceutical supply chains that can help address some of the most pressing health challenges of our time.

7. Conclusion

The convergence of AI, blockchain, and pharmacoeconomics offers a transformative approach to building adaptive pharmaceutical supply chains that can address some of the most persistent challenges in global healthcare, including inefficiencies, access disparities, and cost barriers. These technologies, when integrated, create a powerful system that can optimize drug distribution, enhance transparency, and promote equitable access to essential medicines, especially in underserved regions. AI provides the predictive capabilities to anticipate and manage demand, optimize inventory, and reduce waste, while blockchain ensures transparency, security, and traceability, safeguarding against issues such as counterfeit drugs and supply chain fraud. Pharmacoeconomics, meanwhile, plays a critical role in assessing the cost-effectiveness of pharmaceutical interventions, ensuring that drugs are affordable and accessible, and evaluating the broader socio-economic impact of pharmaceutical policies.

As this paradigm develops, it becomes clear that a holistic approach—incorporating technological, economic, and policy dimensions—is necessary to build resilient and efficient pharmaceutical supply chains. The application of AI, blockchain, and pharmacoeconomics not only promises improvements in operational efficiency but also in the equitable distribution of healthcare resources, addressing the critical issue of global drug access. By reducing inefficiencies, ensuring drug provenance, and optimizing cost-effectiveness, this convergence lays the foundation for a more accessible and sustainable healthcare system worldwide.

However, the potential of this approach can only be realized through ongoing collaboration among various stakeholders, including governments, the private sector, international organizations, and non-governmental entities. The successful implementation of these technologies requires concerted efforts to build the necessary infrastructure, overcome regulatory barriers, and ensure ethical use, particularly in low-resource settings. Furthermore, scaling these innovations globally will require a careful, region-specific approach to adapt solutions to local needs and circumstances.

In conclusion, the convergence of AI, blockchain, and pharmacoeconomics represents an unprecedented opportunity to reshape pharmaceutical supply chains in ways that can make global drug access more equitable, transparent, and efficient. Stakeholders must come together to leverage these technologies' full potential, ensuring that the vision of an adaptive, equitable healthcare system is realized for all. The call to action is clear: to embrace innovation, foster collaboration, and prioritize the health and well-being of underserved populations. Through this collective effort, we can drive systemic change and create a future where essential medicines are accessible to every individual, regardless of geographic or socio-economic barriers.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

Reference

[1] Agrawal, P., Barton, I., Dal Bianco, R., Hovig, D., Sarley, D., & Yadav, P. (2016). Moving medicine, moving minds: helping developing countries overcome barriers to outsourcing health commodity distribution to boost supply chain performance and strengthen health systems. *Global Health: Science and Practice*, *4*(3), 359-365.

[2] Agupugo, C. P., & Tochukwu, M. F. C. (2021): A model to Assess the Economic Viability of Renewable Energy Microgrids: A Case Study of Imufu Nigeria.

[3] Agupugo, C. P., Ajayi, A. O., Nwanevu, C., & Oladipo, S. S. (2022); Advancements in Technology for Renewable Energy Microgrids.

[4] Agupugo, C. P., Ajayi, A. O., Nwanevu, C., & Oladipo, S. S. (2022): Policy and regulatory framework supporting renewable energy microgrids and energy storage systems.

[5] Alemede, V., Usuemerai, P. A., & Ibikunle, O. E. (2022). Data-driven strategies for optimizing pharmaceutical supply chains in the United States: A framework for entrepreneurial excellence.

[6] Allen, P. (2015). *Together at the table: Sustainability and sustenance in the American agrifood system*. Penn State Press.

[7] Amimo, F., Lambert, B., Magit, A., & Hashizume, M. (2021). A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa. *Globalization and health*, *17*, 1-15.

[8] Anyika, E. N. (2014). Challenges of implementing sustainable health care delivery in Nigeria under environmental uncertainty. *Journal of Hospital Administration*, *3*(6), 113-126.

[9] Arden, N. S., Fisher, A. C., Tyner, K., Lawrence, X. Y., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International Journal of Pharmaceutics*, *602*, 120554.

[10] Ardill, L., O'Reilly, K., Brinth, A., Fitzgerald, C., & Huss, T. (2022). Sarah Cronin Health XL, Dublin, Ireland Sophie Madden Health XL, Dublin, Ireland. *Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects*, 405.

[11] Aruru, M., Truong, H. A., & Clark, S. (2021). Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. *Research in Social and Administrative Pharmacy*, *17*(1), 1967-1977.

[12] Asibor, J. O., & Ighodaro, O. (2019). Steady State Analysis of Nanofuel Droplet Evaporation. *International Journal of Nanoscience and Nanotechnology*, *15*(3), 145-155.

[13] Aung, M. M., & Chang, Y. S. (2014). Traceability in a food supply chain: Safety and quality perspectives. Food control, 39, 172-184.

[14] Barbosa, F., Woetzel, J., & Mischke, J. (2017). *Reinventing construction: A route of higher productivity*. McKinsey Global Institute.

[15] Barcevičius, E., Cibaitė, G., Codagnone, C., Gineikytė, V., Klimavičiūtė, L., Liva, G., ... & Vanini, I. (2019). Exploring Digital Government transformation in the EU. *Publications Office of the European Union, Luxembourg*.

[16] Bates, D. W., Saria, S., Ohno-Machado, L., Shah, A., & Escobar, G. (2014). Big data in health care: using analytics to identify and manage high-risk and high-cost patients. *Health affairs*, *33*(7), 1123-1131.

[17] Bello, O. A., Folorunso, A., Ogundipe, A., Kazeem, O., Budale, A., Zainab, F., & Ejiofor, O. E. (2022). Enhancing Cyber Financial Fraud Detection Using Deep Learning Techniques: A Study on Neural Networks and Anomaly Detection. *International Journal of Network and Communication Research*, *7*(1), 90-113.

[18] Berman, E. M., Bowman, J. S., West, J. P., & Van Wart, M. R. (2021). *Human resource management in public service: Paradoxes, processes, and problems*. Cq Press.

[19] Chanchaichujit, J., Tan, A., Meng, F., Eaimkhong, S., Chanchaichujit, J., Tan, A., ... & Eaimkhong, S. (2019). Innovative Health Technologies and Start-Ups Process in Healthcare Industry. *Healthcare 4.0: Next Generation Processes with the Latest Technologies*, 123-159.

[20] Dash, R., McMurtrey, M., Rebman, C., & Kar, U. K. (2019). Application of artificial intelligence in automation of supply chain management. *Journal of Strategic Innovation and Sustainability*, *14*(3).

[21] De Boeck, K., Decouttere, C., Jónasson, J. O., & Vandaele, N. (2022). Vaccine supply chains in resource-limited settings: mitigating the impact of rainy season disruptions. *European Journal of Operational Research*, *301*(1), 300-317.

[22] De Castro, L., Lopez, A. A., Hamoy, G., Alba, K. C., & Gundayao, J. C. (2021). A fair allocation approach to the ethics of scarce resources in the context of a pandemic: The need to prioritize the worst-off in the Philippines. *Developing world bioethics*, *21*(4), 153-172.

[23] Egware, H. O., Ighodaro, O. O., & Unuareokpa, O. J. (2016). Experimental design and fabrication of domestic water heating from solid waste incinerator. *Journal of Civil and Environmental Systems Engineering, 14*(1), 180–192.

[24] Egware, H. O., Obanor, A. I., Aniekwu, A. N., Omoifo, O. I., & Ighodaro, O. O. (2021). Modelling and simulation of the SGT5–2000E gas turbine model for power generation. *Journal of Energy Technology and Environment*, *3*(2).

[25] Egware, H. O., Onochie, U. P., & Ighodaro, O. O. (2016). Prospects of wind energy for power generation in university of Benin. *Int. J. of Thermal & Environmental Engineering*, *13*(1), 23-28.

[26] Elbadawi, M., McCoubrey, L. E., Gavins, F. K., Ong, J. J., Goyanes, A., Gaisford, S., & Basit, A. W. (2021). Harnessing artificial intelligence for the next generation of 3D printed medicines. *Advanced Drug Delivery Reviews*, *175*, 113805.

[27] Elujide, I., Fashoto, S. G., Fashoto, B., Mbunge, E., Folorunso, S. O., & Olamijuwon, J. O. (2021). Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. *Informatics in Medicine Unlocked*, *23*, 100545.

[28] Elujide, I., Fashoto, S. G., Fashoto, B., Mbunge, E., Folorunso, S. O., & Olamijuwon, J. O. (2021). Informatics in Medicine Unlocked.

[29] Euchi, J. (2021). Do drones have a realistic place in a pandemic fight for delivering medical supplies in healthcare systems problems?. *Chinese Journal of Aeronautics*, *34*(2), 182-190.

[30] Feitshans, I. L. (2022). Global Health Technologies Transforming Intellectual Property Law and World Trade. *Precision Nanomedicine*, *5*(4), 977-993.

[31] Ganesh, A. D., & Kalpana, P. (2022). Future of artificial intelligence and its influence on supply chain risk management–A systematic review. *Computers & Industrial Engineering*, *169*, 108206.

[32] Garbuio, M., & Lin, N. (2018). A Cognitive Perspective. *Entrepreneurship in Healthcare*.

[33] Gichuki, N. (2021). Challenges of devolved health care in Kenya: an analysis of the policy and legislative framework. *KAS African Law Study Library*, *7*(4), 501-524.

[34] Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: from science to value. *Health affairs*, *37*(5), 694-701.

[35] Greenwood, B. (2014). The contribution of vaccination to global health: past, present and future. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *369*(1645), 20130433.

[36] Gunders, D., & Bloom, J. (2017). Wasted: How America is losing up to 40 percent of its food from farm to fork to landfill.

[37] Helo, P., & Hao, Y. (2022). Artificial intelligence in operations management and supply chain management: An exploratory case study. *Production Planning & Control*, *33*(16), 1573-1590.

[38] Hendrickson, M. K., Howard, P. H., Miller, E. M., & Constance, D. H. (2020). The food system: Concentration and its impacts. *A Special Report to the Family Farm Action Alliance*, *26*, 1-26.

[39] Hope Sr, K. R. (2017). *Corruption and Governance in Africa: Swaziland, Kenya, Nigeria*. Springer.

[40] Horgan, D., Borisch, B., Richer, E., Bernini, C., Kalra, D., Lawler, M., ... & Jonsson, B. (2020). Propelling health care into the twenties. *Biomedicine hub*, *5*(2), 1-53.

[41] Ighodaro, O. O. (2010). Reliability and availability analysis of gas turbine plants. *International Journal of Engineering and Technology, 2*(1), 38–50.

[42] Ighodaro, O. O. (2016). *Modelling and simulation of intermediate temperature solid oxide fuel cells and their integration in hybrid gas turbine plants* (Doctoral dissertation, Newcastle University).

[43] Ighodaro, O. O., & Aburime, B. A. (2011). Exergetic appraisal of Delta IV power station, Ughelli. *Journal of Emerging Trends in Engineering and Applied Sciences*, *2*(2), 216-218.

[44] Ighodaro, O. O., & Agbro, E. B. (2010). Efficiency Analysis of Power Generation in Gas Turbine Plants. *International Journal of Natural and Applied Sciences*, *2*(1), 20-31.

[45] Ighodaro, O. O., & Aregbe, O. (2017). Conceptual design and fabrication of a dual powered self cleaning marker board. *Journal of the Nigerian Association of Mathematical Physics*, *39*, 379-384.

[46] Ighodaro, O. O., & Egbon, O. C. (2021). Comparative Performance Assessment of Different Gas Turbine Configurations: A Study of a Local Power Station in Nigeria. *Nigerian Journal of Engineering*, *28*(2).

[47] Ighodaro, O. O., & Egwaoje, S. O. (2020). Design and Feasibility Study of a PV-Micro Hydro Off-Grid Power Generating System. *NIPES-Journal of Science and Technology Research*, *2*(1).

[48] Ighodaro, O. O., & Egware, H. O. (2014). Experimental design and fabrication of displacer-type Stirling engine for small-scale electricity generation. *University of Benin Journal of Science and Technology, 2*(1), 96–103.

[49] Ighodaro, O. O., & Essien, N. F. (2020). Experimental Analysis on the Characteristics of Pulverized Coal-Palm kernel Shell Fuel Blend. *CaJoST*, *2*(2), 89-93.

[50] Ighodaro, O. O., & Orumwense, E. F. (2022). Performance analysis and ranking of selected organic fluids for use in an organic Rankine cycle. *Journal of Engineering for Development, 14*(3), 82–91.

[51] Ighodaro, O. O., & Osikhuemhe, M. (2019). Numerical investigation of the effect of tyre inflation pressure on fuel consumption in automobiles. *Nigerian Journal of Technological Research*, *14*(2), 38-47.

[52] Ighodaro, O. O., & Osikhuemhe, M. (2019). Thermo-economic analysis of a heat recovery steam generator combined cycle. *Nigerian Journal of Technology*, *38*(2), 342-347.

[53] Ighodaro, O. O., & Saale, G. B. (2017). Performance and exergy analysis of boiler (101-B-01) system at the Warri Refining and Petrochemical Company. *Journal of the Nigerian Association of Mathematical Physics*, *39*, 369-378.

[54] Ighodaro, O. O., & Scott, K. (2017). Polarisation modelling of an anode-supported solid oxide fuel cell. *Research Journal of Engineering and Environmental Sciences, 2*(1), 18–31.

[55] Ighodaro, O. O., Aburime, E. I., & Erameh, A. A. (2022). Off-design modelling of a turbo jet engine with operative afterburner. *Open Journal of Energy Efficiency*, *11*(3), 88-107.

[56] Ighodaro, O. O., Ilori, S. O., Aburime, E. I., & Obanor, A. I. (2022). An equilibrium model of NOx emission in gas turbine combustors. *Nigerian Journal of Technology*, *41*(4), 778-788.

[57] Ighodaro, O. O., Okogie, S., & Ozakpolor, J. (2010). Design and modelling of a wind power generating plant. *Journal of Engineering and Applied Science, 2*(1), 82–92.

[58] Ighodaro, O. O., Olaosebikan, F., & Egware, H. O. (2020). Technical analysis and economic assessment of a standalone solar PV/fuel cell hybrid power system. *Nigerian Journal of Engineering Science Research, 3*(1), 27–34.

[59] Ighodaro, O. O., Scott, K., & Xing, L. (2017). An isothermal study of the electrochemical performance of intermediate temperature solid oxide fuel cells. *Journal of Power and Energy Engineering*, *5*(2), 97-122.

[60] Ighodaro, O., & Akhihiero, D. (2021). Modeling and performance analysis of a small horizontal axis wind turbine. *Journal of Energy Resources Technology*, *143*(3), 031301.

[61] Ighodaro, O., & Scott, K. (2013): Numerical Modelling of Solid Oxide Fuel Cells: Role of Various Cell Parameters on Performance.

[62] Ighodaro, O., Ochornma, P., & Egware, H. (2020). Energy Analysis of A Retrofitted Regenerative Gas Turbine Organic Cycle in Ihovbor Power Plant. *International Journal of Engineering Technologies IJET*, *6*(3), 45-61.

[63] Iyamu, I., Gómez-Ramírez, O., Xu, A. X., Chang, H. J., Watt, S., Mckee, G., & Gilbert, M. (2022). Challenges in the development of digital public health interventions and mapped solutions: findings from a scoping review. *Digital health*, *8*, 20552076221102255.

[64] Kaul, D., & Khurana, R. (2022). Ai-driven optimization models for e-commerce supply chain operations: Demand prediction, inventory management, and delivery time reduction with cost efficiency considerations. *International Journal of Social Analytics*, *7*(12), 59-77.

[65] Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: a review. *The AAPS journal*, *24*, 1-10.

[66] Krumholz, H. M. (2014). Big data and new knowledge in medicine: the thinking, training, and tools needed for a learning health system. *Health Affairs*, *33*(7), 1163-1170.

[67] Kulkov, I. (2021). The role of artificial intelligence in business transformation: A case of pharmaceutical companies. *Technology in Society*, *66*, 101629.

[68] Kwasi-Effah, C. C., Ighodaro, O., Egware, H. O., & Obanor, A. I. (2022). Characterization and comparison of the thermophysical property of ternary and quaternary salt mixtures for solar thermal power plant applications. *Results in Engineering*, *16*, 100721.

[69] Kwasi-Effah, C. C., Ighodaro, O., Egware, H. O., & Obanor, A. I. (2022). A novel empirical model for predicting the heat accumulation of a thermal energy storage medium for solar thermal applications. *Journal of Energy Storage*, *56*, 105969.

[70] Maureen, L. (2017). Corruption in public health. In *Fighting the Diseases of Poverty* (pp. 63-125). Routledge.

[71] Mettler, T., & Naous, D. (2022). Beyond panoptic surveillance: On the ethical dilemmas of the connected workplace. In *ECIS*.

[72] Micalo, S. (2022). *Healthtech Innovation: How Entrepreneurs Can Define and Build the Value of Their New Products*. CRC Press.

[73] Modgil, S., Singh, R. K., & Hannibal, C. (2022). Artificial intelligence for supply chain resilience: learning from Covid-19. *The International Journal of Logistics Management*, *33*(4), 1246-1268.

[74] Nursimulu, A. (2019). Value Creation in Precision Medicine: Acknowledging the Need to Devise New Ways to Measure. The Value of Healthcare.

[75] Nychas, G. J. E., Panagou, E. Z., & Mohareb, F. (2016). Novel approaches for food safety management and communication. Current Opinion in Food Science, 12, 13-20.

[76] Okagbare, G. O., Omotehinse, S. A., & Ighodaro, O. O. (2022). An Investigation of the Hydro-Power Potential of the Ojirami Dam in Nigeria. *Journal of Energy Technology and Environment*, *4*(2).

[77] Onochie, U. P. (2019). A comprehensive review on biomass pelleting Technology and electricity generation from biomass. *Journal of Energy Technology and Environment*, *1*.

[78] Onochie, U. P. (2020). Evaluating the Energy Cost Benefit of a Biomass Fired Combined Heat and Power Plant. *NIPES-Journal of Science and Technology Research*, *2*(1).

[79] Onochie, U. P., & Ighodaro, O. O. (2017). Power generation potential from fuel pellets developed from oil palm residues. *African Journal of Renewable and Alternative Energy, 2*(3), 32–38.

[80] Onochie, U. P., Ighodaro, O. O., Kwasi-Effah, C. C., & Otomi, K. O. (2018). One dimensional simulation of extrusion channel of biomass pelleting machine. *Journal of Applied Sciences and Environmental Management*, *22*(8), 1213-1217.

[81] Onochie, U. P., Madagwu, L. O., Kwasi-Effah, C. C., Ighodaro, O. O., Kubeynje, B. F., Akingba, O. O., & Damisah, L. E. (2022). Energy Audit of a Solar Panel Manufacturing Plant: A Case Study of NASENI Solar Panel Plant, Karshi, Abuja. *Journal of Energy Technology and Environment*, *4*(1).

[82] Onochie, U. P., Obanor, A. I., & Ighodaro, O. O. (2017). Combustion performance and durability analysis of biomass fuel pellets from oil palm residues.

[83] Onochie, U. P., Obanor, A. I., Aliu, S. A., & Igbodaro, O. O. (2017). Proximate and ultimate analysis of fuel pellets from oil palm residues. *Nigerian Journal of Technology*, *36*(3), 987-990.

[84] Onochie, U. P., Obanor, A. I., Aliu, S. A., & Ighodaro, O. O. (2017). Determination of some thermal characteristics of fuel pellets obtained from oil palm residues. *J. Natl. Assoc. Math. Phys*, *40*, 447-450.

[85] Onochie, U. P., Obanor, A. L., Aliu, S. A., & Ighodaro, O. O. (2017). Fabrication and performance evaluation of a pelletizer for oil palm residues and other biomass waste materials. *Journal of the Nigerian Association of Mathematical Physics*, *40*, 443-446.

[86] Onyeke, F. O., Odujobi, O., Adikwu, F. E. & Elete, T. Y., 2022. Innovative approaches to enhancing functional safety in Distributed Control Systems (DCS) and Safety Instrumented Systems (SIS) for oil and gas applications. Open Access Research Journal of Multidisciplinary Studies, 3(1), pp. 106–112. Available at: <https://doi

[87] Onyeke, F. O., Odujobi, O., Adikwu, F. E. & Elete, T. Y., 2022. Innovative approaches to enhancing functional safety in Distributed Control Systems (DCS) and Safety Instrumented Systems (SIS) for oil and gas applications. Open Access Research Journal of Multidisciplinary Studies, 3(1), pp. 106–112. Available at: <https://doi

[88] Onyiriuka, E. J., Ighodaro, O. O., Adelaja, A. O., Ewim, D. R. E., & Bhattacharyya, S. (2019). A numerical investigation of the heat transfer characteristics of water-based mango bark nanofluid flowing in a double-pipe heat exchanger. *Heliyon*, *5*(9).

[89] Orumwense, E. F., Ighodaro, O. O., & Abo-Al-Ez, K. (2021). Energy growth and sustainability through smart grid approach: a case study of the Nigeria Electric grid. *International Review of Electrical Engineering (IREE)*, *16*(6), 542-551.

[90] Osarobo, I., & Chika, A. (2016). Neural network modeling for monitoring petroleum pipelines. *International Journal of Engineering Research in Africa*, *26*, 122-131.

[91] Parouty, M. (2018). e-HEAL protocol.

[92] Riahi, Y., Saikouk, T., Gunasekaran, A., & Badraoui, I. (2021). Artificial intelligence applications in supply chain: A descriptive bibliometric analysis and future research directions. *Expert Systems with Applications*, *173*, 114702.

[93] Roxon, L. (2018). Data That Heals: A Three Horizon Analysis. *x*.

[94] Sarker, S., Henningsson, S., Jensen, T., & Hedman, J. (2021). The use of blockchain as a resource for combating corruption in global shipping: an interpretive case study. *Journal of Management Information Systems*, *38*(2), 338-373.

[95] Seshaiyer, P., & McNeely, C. L. (2020). Challenges and opportunities from COVID-19 for global sustainable development. *World Medical & Health Policy*, *12*(4), 443-453.

[96] Shafique, S., Bhattacharyya, D. S., Anwar, I., & Adams, A. (2018). Right to health and social justice in Bangladesh: ethical dilemmas and obligations of state and non-state actors to ensure health for urban poor. *BMC medical ethics*, *19*, 61-69.

[97] Sun, Z., & Zhang, Y. (2022). Strategic crisis response of shipping industry in the post COVID-19 era: A case of the top 10 shipping lines. *Journal of Marine Science and Engineering*, *10*(5), 635.

[98] Tzenios, N. (2019). The determinants of Access to Healthcare: a review of Individual, Structural, and systemic factors. *Journal of Humanities and Applied Science Research*, *2*(1), 1-14.

[99] Van Rensburg, H. C. (2014). South Africa's protracted struggle for equal distribution and equitable access–still not there. *Human resources for health*, *12*, 1-16.

[100] Whitney, E. (2022). *Uses of Agent-Based Modeling and Simulation to Support Business Decision-Making for Healthcare Industry Leadership in the United States of America* (Doctoral dissertation, Northcentral University).

[101] World Health Organization. (2016). Working for health and growth: investing in the health workforce.